Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sophie Shubow
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0009-0007-1087-4261
Observed ORCID:
0009-0007-1087-4261
OpenAlex ID:
A5026692930
Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors
2025
·
Montserrat Puig
, Sophie Shubow
·
Frontiers in Immunology
·
41
PDF
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization)
2024
·
Johanna Mora
, Rachel Palmer
, et al.
·
Bioanalysis
·
24
PDF
Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary
2022
·
Sophie Shubow
, Qin Sun
, et al.
·
Clinical Pharmacology & Therapeutics
·
22
PDF
2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine)
2024
·
Mike Baratta
, Wenying Jian
, et al.
·
Bioanalysis
·
17
PDF
Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary
2022
·
Jeffry Florian
, Qin Sun
, et al.
·
Clinical Pharmacology & Therapeutics
·
16
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report
2025
·
Sophie Shubow
, Michele Gunsior
, et al.
·
The AAPS Journal
·
12
PDF
2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS ( PART 3A – Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance PART 3B – Regulatory Agencies’ Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)
2025
·
Omar Tounekti
, Sophie Shubow
, et al.
·
Bioanalysis
·
6
PDF
Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products
2026
·
Jennifer K. Lee
, Ha-Na Lee
, et al.
·
The AAPS Journal
·
1
PDF
The Need for Clinical Trial Dataset Specifications to Support Clinical Pharmacology Review of Immunogenicity
2026
·
Sophie Shubow
, Mohsen Rajabi Abhari
, et al.
·
The AAPS Journal
Show more works
View as search
Works count:
9
Citation count:
139
H-index:
6
I10-index:
6
Year
Topic
Type